中國醫療網絡(00383.HK)預期年度虧損3000萬-6000萬安港
格隆匯 1 月 21日丨中國醫療網絡(00383.HK)公佈,預期集團於截至2020年12月31日止年度將錄得公司股東應占虧損(或會作出任何進一步減值、有關應收貸款之調整或其他調整)介乎約3000萬港元至6000萬安港元,而2019年同期(十八個月)則錄得純利約220萬港元。
此乃主要由於(i)受COVID-19大流行之負面影響,醫療分部及護老分部業務產生之收益減少;(ii)自放債業務並無收取利息收入;(iii)持作買賣之投資公允價值錄得虧損,而2019年同期(十八個月)則錄得收益;及(iv)就金融資產確認減值虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.